HAE Haemonetics Corp

Price (delayed)

$120.25

Market cap

$6.11B

P/E Ratio

56.19

Dividend/share

N/A

EPS

$2.14

Enterprise value

$6.23B

Sector: Healthcare
Industry: Medical Instruments & Supplies

Highlights

The company's quick ratio rose by 49% YoY and by 40% QoQ
The company's EPS rose by 36% YoY
The revenue fell by 12% YoY and by 2.1% QoQ
The company's gross profit fell by 11% YoY

Key stats

What are the main financial stats of HAE
Market
Shares outstanding
50.82M
Market cap
$6.11B
Enterprise value
$6.23B
Valuations
Price to earnings (P/E)
56.19
Price to book (P/B)
8.49
Price to sales (P/S)
6.91
EV/EBIT
45.51
EV/EBITDA
27.33
EV/Sales
7.05
Earnings
Revenue
$883.93M
EBIT
$136.93M
EBITDA
$228.07M
Free cash flow
$119.21M
Per share
EPS
$2.14
Free cash flow per share
$2.35
Book value per share
$14.16
Revenue per share
$17.4
TBVPS
$19.35
Balance sheet
Total assets
$1.32B
Total liabilities
$598.92M
Debt
$309.78M
Equity
$719.15M
Working capital
$473.96M
Liquidity
Debt to equity
0.43
Current ratio
3.44
Quick ratio
1.73
Net debt/EBITDA
0.53
Margins
EBITDA margin
25.8%
Gross margin
48.6%
Net margin
12.2%
Operating margin
15.5%
Efficiency
Return on assets
8%
Return on equity
16.7%
Return on invested capital
15%
Return on capital employed
12.2%
Return on sales
15.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HAE stock price

How has the Haemonetics stock price performed over time
Intraday
0.55%
1 week
-4.94%
1 month
-13.63%
1 year
16.48%
YTD
1.26%
QTD
1.26%

Financial performance

How have Haemonetics's revenue and profit performed over time
Revenue
$883.93M
Gross profit
$429.59M
Operating income
$136.93M
Net income
$108.13M
Gross margin
48.6%
Net margin
12.2%
The operating margin has soared by 53% YoY
The net margin has soared by 53% year-on-year and by 3.4% since the previous quarter
HAE's net income is up by 36% year-on-year
The operating income is up by 35% year-on-year

Growth

What is Haemonetics's growth rate over time

Valuation

What is Haemonetics stock price valuation
P/E
56.19
P/B
8.49
P/S
6.91
EV/EBIT
45.51
EV/EBITDA
27.33
EV/Sales
7.05
The company's EPS rose by 36% YoY
The price to earnings (P/E) is 7% higher than the last 4 quarters average of 52.5
The price to book (P/B) is 42% higher than the 5-year quarterly average of 6.0 and 10% higher than the last 4 quarters average of 7.7
The equity is up by 25% year-on-year and by 8% since the previous quarter
The stock's P/S is 65% more than its 5-year quarterly average of 4.2 and 28% more than its last 4 quarters average of 5.4
The revenue fell by 12% YoY and by 2.1% QoQ

Efficiency

How efficient is Haemonetics business performance
The company's return on sales has surged by 53% YoY
The company's return on invested capital rose by 32% YoY
HAE's return on equity is up by 27% year-on-year but it is down by 4% since the previous quarter
The company's return on assets rose by 25% YoY

Dividends

What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HAE.

Financial health

How did Haemonetics financials performed over time
The total assets is 120% more than the total liabilities
The current ratio has soared by 53% from the previous quarter and by 52% YoY
The company's quick ratio rose by 49% YoY and by 40% QoQ
The debt is 57% smaller than the equity
The debt to equity has contracted by 38% from the previous quarter and by 34% YoY
The debt is down by 33% since the previous quarter and by 17% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.